NCT00753545 2025-02-03
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
AstraZeneca
Phase 2 Completed
AstraZeneca
Mario Negri Institute for Pharmacological Research
AstraZeneca
Catholic University of the Sacred Heart
Amgen